Evolution of payment models for cell and gene therapies in Italy

By Joanna Fernandes, Associate Consultant Email: jfernandes@partners4access.com Cell and gene therapies (CGTs) are considered one-time transformative treatments, positioned as having life-long benefits. These new therapies are challenging the traditional business model, with health technology assessment (HTA) and reimbursement processes having been established around chronic therapies. This has led to one of the biggest hurdles currently…

Future-proofing 2019 plans: P4A’s 6 Orphan Drug, Cell & Gene Therapy trends to watch out for

2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will be new treatment launches particularly from cell and gene therapies. As these novel therapies are geared towards commercialization, the industry is witnessing a change in approach by manufacturers, regulators and…

Sustainable funding of cell and gene therapies: bluebird bio puts the ball in the payer’s court

By Nader Murad, Associate Consultant Email: nmurad@partners4access.com At JPMorgan’s  37th Healthcare Conference in 2019, bluebird bio provided its strategic outlook and plans for the year where it highlighted its pipeline progress and commercial activities. bluebird’s pipeline consists of several gene therapies which have demonstrated in clinical studies a high likelihood of potentially curing severe rare…

P4A to present Cell & Gene Therapy insights at WODC 2018

Partners4Access, a leading market access consultancy specializing in orphan drugs, cell and gene therapy today announced its participation at the World Orphan Drug Congress, an industry conference that brings together rare disease stakeholders under a common platform. The three-day event is being held between November 6-8, 2018 in Barcelona, Spain. P4A’s Sophie Schmitz, Managing Partner…